联合肝表面结节度与血清学指标可更准确预测慢性肝病肝纤维化分期
本研究基于CT图像量化肝表面结节度,并与血清纤维化指标联合建立线性模型,在125例开发组和183例验证组中评估其对慢性肝病(主要为慢性乙型肝炎)肝纤维化分期的预测效能。结果显示,联合模型预测肝硬化、进展期纤维化和显著纤维化的AUC均高于单用血清学指标,提示联合方法可提高无创分期准确性。
要点
- CT肝表面结节度与血清学指标联合模型预测肝硬化AUC达0.901,优于血清学指标单独应用。
- 联合模型对进展期纤维化(≥F3)和显著纤维化(≥F2)的AUC分别为0.872和0.794。
- 验证组中联合模型同样保持较高AUC,支持其作为无创肝纤维化分期辅助工具。
关键影像表现/征象
- 肝表面结节度与血清纤维化指标均与纤维化分期显著相关。
- 在二分类判断肝硬化(F4)、进展期纤维化(≥F3)和显著纤维化(≥F2)时,肝表面结节度在不同类别间有显著差异。
诊断标准与关键数值
- 最佳联合模型预测肝硬化(F4)的AUC为0.901,高于血清学指标的0.797-0.802。
- 最佳联合模型预测进展期纤维化(≥F3)的AUC为0.872,高于血清学指标的0.799-0.818。
- 最佳联合模型预测显著纤维化(≥F2)的AUC为0.794,高于血清学指标的0.761-0.773。
- 验证组中同一联合模型预测肝硬化、进展期纤维化和显著纤维化的AUC分别为0.872、0.831和0.850。
- 验证组血清学指标对应AUC分别为0.722-0.776、0.692-0.768和0.695-0.769,联合模型对F4的P值<0.001。
临床应用与阅片要点
- 日常阅片时可关注CT图像上肝表面结节度这一征象,并考虑将其与血清学纤维化指标联合用于无创分期。
- 联合模型有助于提高对肝硬化及进展期纤维化的识别准确性,可作为血清学指标之外的补充信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: Hepatic surface nodularity quantified on CT images has shown promising results in staging hepatic fibrosis in chronic hepatitis C. The aim of this study was to evaluate hepatic surface nodularity, serum fibrosis indices, and a linear combination of them for staging fibrosis in chronic liver disease, mainly chronic hepatitis B.
METHODS: We developed a semiautomated software quantifying hepatic surface nodularity on CT images. Hepatic surface nodularity and serum fibrosis indices were assessed in the development group of 125 patients to generate 3 linear models combining hepatic surface nodularity with the aspartate aminotransferase to platelet ratio index, fibrosis-4 index, or platelet count in reference to the METAVIR scoring system. The models were validated in 183 patients.
RESULTS: Hepatic surface nodularity and serum fibrosis indices all significantly correlated with fibrosis stages. For binary classifications into cirrhosis (F4), advanced fibrosis (≥ F3), and significant fibrosis (≥ F2), hepatic surface nodularity was significantly different across categories. The areas under the curve (AUCs) of the best model were 0.901, 0.872, and 0.794 for cirrhosis, advanced fibrosis, and significant fibrosis, respectively, higher than serum fibrosis indices alone (0.797-0.802, 0.799-0.818, and 0.761-0.773). In the validation group, the same model likewise showed higher AUCs (0.872, 0.831, and 0.850) compared to serum fibrosis indices (0.722-0.776, 0.692-0.768, and 0.695-0.769; p < 0.001 for F4).
CONCLUSION: Hepatic surface nodularity combined with serum blood test could be a practical method to predict cirrhosis, advanced fibrosis, and significant fibrosis in chronic liver disease patients, providing higher accuracy than using serum fibrosis indices alone.
引用
- Cho HJ, Choi J, Kim B, et al. Combining hepatic surface nodularity and serum tests better predicts hepatic fibrosis stages in chronic liver disease. Abdom Radiol (NY). 2021. PMID: 33977353. doi:10.1007/s00261-021-03113-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。